Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 124-145 , March 2009

Functional Imaging of Inflammatory Diseases Using Nuclear Medicine Techniques

  • Sandip Basu, MBBS (Hons), DRM, DNB, MNAMS

      Affiliations

    • Radiation Medicine Center (BARC), Tata Memorial Hospital Annex, Mumbai, India
    • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Hongming Zhuang, MD, PhD

      Affiliations

    • Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA
    • ,
  • Drew A. Torigian, MD, MA

      Affiliations

    • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Joshua Rosenbaum, BA

      Affiliations

    • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Wengen Chen, MD, PhD

      Affiliations

    • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Abass Alavi, MD, PhD (Hon), DSc (Hon)

      Affiliations

    • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to Abass Alavi, MD, PhD (Hon), DSc (Hon), Department of Radiology, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 110 Donner Building, 3400 Spruce St, Philadelphia, PA 19104

References 

  1. Zhuang HM, Cortes-Blanco A, Pourdehnad M, et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?. Nucl Med Commun. 2001;22:1123–1128
  2. U.S. Food and Drug Administration: FDA Public Health Advisory: Suspended Marketing of NeutroSpec (Technetium 99mTc fanolesomab). December 19, 2005. Available at: http://www.fda.gov/CDER/drug/advisory/technetium99m.htm. Accessed November 27, 2007
  3. Gross MD, Shapiro B, Fig LM, et al. Imaging of human infection with (131)I-labeled recombinant human interleukin-8. J Nucl Med. 2001;42:1656–1659
  4. Amartey JK, Esguerra C, Al-Otaibi B, et al. Prosthetic radioiodination of interleukin-8 ([(123/131)I]-IL-8): Biological behavior in a mouse infection model. Appl Radiat Isot. 2005;62:39–47
  5. van der Laken CJ, Boerman OC, Oyen WJ, et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: A comparative study. Eur J Nucl Med. 1998;25:347–352
  6. Signore A, Chianelli M, Annovazzi A, et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med. 2000;41:242–249
  7. Moyer BR, Vallabhajosula S, Lister-James J, et al. Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl Med. 1996;37:673–679
  8. Annovazzi A, Biancone L, Caviglia R, et al. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Chrohn's disease. Eur J Nucl Med Mol Imaging. 2003;30:374–382
  9. Diot P, Diot E, Lemarie E, et al. Imaging of pulmonary disease in scleroderma with J001X scintigraphy. Thorax. 1994;49:504–508
  10. Diot P, Le Pape A, Nolibe D, et al. Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berylliosis: Results from an experimental model. Br J Ind Med. 1992;49:359–364
  11. Ohtsuki K, Hayase M, Akashi K, et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study. Circulation. 2001;104:203–208
  12. Yu JQ, Zhuang H, Mavi A, et al. Evaluating the role of fluorodeoxyglucose PET imaging in the management of patients with sarcoidosis. PET Clin. 2006;1:141–152
  13. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21–26
  14. Shorr AF, Helman DL, Lettieri CJ, et al. Depreotide scanning in sarcoidosis: A pilot study. Chest. 2004;126:1337–1343
  15. Hughes JM, Rhodes CG, Brudin LH, et al. Contribution of the positron camera to studies of regional lung structure and function. Eur J Nucl Med. 1987;13(suppl):S37–S41
  16. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med. 1994;35:1650–1652
  17. Larson SM. Cancer or inflammation? (A Holy Grail for nuclear medicine). J Nucl Med. 1994;35:1653–1655
  18. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59
  19. El-Haddad G, Zhuang H, Gupta N, et al. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313–329
  20. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–1543
  21. Xiu Y, Yu JQ, Cheng E, et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med. 2005;30:193–195
  22. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–1576
  23. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305
  24. Milman N, Mortensen J, Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration. 2003;70:408–413
  25. Prager E, Wehrschuetz M, Bisail B, et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging. Nuklearmedizin. 2008;47:18–23
  26. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–1953
  27. Braun JJ, Kessler R, Constantinesco A, et al. (18)F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;
  28. Hain SF, Beggs AD. C-11 methionine uptake in granulomatous disease. Clin Nucl Med. 2004;29:585–586
  29. Halter G, Buck AK, Schirrmeister H, et al. [18F] 3-deoxy-3′-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?. J Thorac Cardiovasc Surg. 2004;127:1093–1099
  30. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160–1166
  31. Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51:179–188
  32. Mana J. Nuclear imaging (67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography). Clin Chest Med. 1997;18:799–811
  33. Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107:330–334
  34. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–1998
  35. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–1036
  36. Kaku B, Kanaya H, Horita Y, et al. Failure of follow-up gallium single-photon emission computed tomography and fluorine-18-fluorodeoxyglucose positron emission tomography to predict the deterioration of a patient with cardiac sarcoidosis. Circ J. 2004;68:802–805
  37. Sponsler JL, Werz MA, Maciunas R, et al. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: Case reports and review of the literature. Epilepsy Behav. 2005;6:623–630
  38. Ng D, Jacobs M, Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med. 2006;31:373–375
  39. Aide N, Benayoun M, Kerrou K, et al. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol. 2007;80:e67–e71
  40. Kobayashi A, Shinozaki T, Shinjyo Y, et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. Ann Nucl Med. 2000;14:311–313
  41. Ludwig V, Fordice S, Lamar R, et al. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med. 2003;28:176–179
  42. Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med. 2001;26:542–543
  43. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  44. Tannen BL, Ghesani NV, Frohman L, et al. Use of whole-body FDG PET-CT to aid in the diagnosis of occult sarcoidosis. Ocul Immunol Inflamm. 2008;16:25–27
  45. Yun M, Jang S, Cucchiara A, et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70–76
  46. Yun M, Yeh D, Araujo LI, et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26:314–319
  47. Wu YW, Kao HL, Chen MF, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med. 2007;48:227–233
  48. Zhang Z, Machac J, Helft G, et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med. 2006;6:3
  49. Ogawa M, Magata Y, Kato T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845–1850
  50. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–896
  51. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–878
  52. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533–1539
  53. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825–1831
  54. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation. 2001;103:926–933
  55. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249–252
  56. Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642–2647
  57. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209–217
  58. Tatsumi M, Cohade C, Nakamoto Y, et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: Possible finding for active atherosclerosis. Radiology. 2003;229:831–837
  59. Bural GG, Torigian DA, Chamroonrat W, et al. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. Nucl Med Biol. 2006;33:1037–1043
  60. Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562–569
  61. Otsuka H, Morita N, Yamashita K, et al. FDG-PET/CT for diagnosis and follow-up of vasculitis. J Med Invest. 2007;54:345–349
  62. Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc. 1993;41:1187–1192
  63. Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin: The challenge continues. Arch Intern Med. 2003;163:1033–1041
  64. Savage CO, Harper L, Cockwell P, et al. ABC of arterial and vascular disease: Vasculitis. Bmj. 2000;320:1325–1328
  65. Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, et al. Giant cell arteritis and polymyalgia rheumatica: Pathophysiology and management. Drugs Aging. 2006;23:627–649
  66. Chong EW, Robertson AJ. Is temporal artery biopsy a worthwhile procedure?. ANZ J Surg. 2005;75:388–391
  67. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261–271
  68. Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford). 1999;38:444–447
  69. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis (A population-based study). Ann Intern Med. 1995;122:502–507
  70. Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730–736
  71. Walter MA, Melzer RA, Schindler C, et al. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32:674–681
  72. Hautzel H, Sander O, Heinzel A, et al. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: Introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49:1107–1113
  73. Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006;55:131–137
  74. Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr. 1999;23:16–18
  75. Theron J, Tyler JL. Takayasu's arteritis of the aortic arch: Endovascular treatment and correlation with positron emission tomography. AJNR Am J Neuroradiol. 1987;8:621–626
  76. Webb M, Chambers A, Al-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004;31:627–634
  77. Andrews J, Al-Nahhas A, Pennell DJ, et al. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis. 2004;63:995–1000
  78. Moosig F, Czech N, Mehl C, et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: A quantitative PET study. Ann Rheum Dis. 2004;63:870–873
  79. Marienhagen J, Geissler A, Lang B. High resolution single photon emission computed tomography of the brain in Wegener's granulomatosis. J Rheumatol. 1996;23:1828–1830
  80. Wildhagen K, Stoppe G, Meyer GJ, et al. [Imaging diagnosis of central nervous system involvement in panarteritis nodosa]. Z Rheumatol. 1989;48:323–325
  81. van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int. 1991;11:1–11
  82. Stoppe G, Wildhagen K, Seidel JW, et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology. 1990;40:304–308
  83. Sailer M, Burchert W, Ehrenheim C, et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol. 1997;244:186–193
  84. Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: Value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis. 2000;59:377–385
  85. Gratz S, Rennen HJ, Boerman OC, et al. Rapid imaging of experimental colitis with (99m)Tc-interleukin-8 in rabbits. J Nucl Med. 2001;42:917–923
  86. Basu S, Torigian D, Alavi A. The role of modern molecular imaging techniques in gastroenterology. Gastroenterology. 2008;135:1055–1061
  87. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics. 1999;19:61–77quiz 150-151
  88. Pio BS, Byrne FR, Aranda R, et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol. 2003;5:271–277
  89. Miraldi F, Vesselle H, Faulhaber PF, et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23:3–7
  90. Lemberg DA, Issenman RM, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:733–738
  91. Loffler M, Weckesser M, Franzius C, et al. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:379–385
  92. Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn's disease activity: A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97:1978–1985
  93. Meisner RS, Spier BJ, Einarsson S, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:993–1000
  94. Louis E, Ancion G, Colard A, et al. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48:1053–1059
  95. Bostel F, Hauger W. 99mTc-nanocolloid: Clinical results of its use as a new inflammation marker. [in German] Rofo. 1988;149:648–653
  96. Vorne M, Lantto T, Paakkinen S, et al. Clinical comparison of 99Tcm-HMPAO labelled leucocytes and 99Tcm-nanocolloid in the detection of inflammation. Acta Radiol. 1989;30:633–637
  97. Makela AL, Soini I, Makela P. Technetium-99m nanocolloid scintigraphy in rheumatic inflammation in children. Acta Univ Carol [Med] (Praha). 1991;37:61–67
  98. Ang ES, Sundram FX, Goh AS, et al. 99Tcm-polyclonal IgG and 99Tcm nanocolloid scans in orthopaedics: A comparison with conventional bone scan. Nucl Med Commun. 1993;14:419–432
  99. Palosaari K, Vuotila J, Takalo R, et al. Contrast-enhanced dynamic and static MRI correlates with quantitative 99Tcm-labelled nanocolloid scintigraphy (Study of early rheumatoid arthritis patients). Rheumatology (Oxford). 2004;43:1364–1373
  100. Breedveld FC, van Kroonenburgh MJ, Camps JA, et al. Imaging of inflammatory arthritis with technetium-99m-labeled IgG. J Nucl Med. 1989;30:2017–2021
  101. Wandler E, Kramer EL, Sherman O, et al. Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis. AJR Am J Roentgenol. 2005;185:797–803
  102. Zhuang H, Chacko TK, Hickeson M, et al. Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur J Nucl Med Mol Imaging. 2002;29:1328–1333
  103. Zhuang H, Sam JW, Chacko TK, et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging. 2003;30:1096–1103
  104. Polisson RP, Schoenberg OI, Fischman A, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:819–825
  105. Ju JH, Kang KY, Kim IJ, et al: Visualization and localization of rheumatoid knee synovitis with FDG-PET/CT images. Clin Rheumatol (in press)
  106. Vogel WV, van Riel PL, Oyen WJ. FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. Eur J Nucl Med Mol Imaging. 2007;34:439
  107. Parsons M, Torigian D, Alavi A. Metabolic activity in the painful knee joint as measured on FDG-PET. J Nucl Med. 2008;49:270P
  108. El-Haddad G, Kumar R, Pamplona R, et al. PET/MRI depicts the exact location of meniscal tear associated with synovitis. Eur J Nucl Med Mol Imaging. 2006;33:507–508
  109. Basu S, Chryssikos T, Houseni M, et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?. Nucl Med Commun. 2007;28:465–472
  110. Houseni M, Chamroonrat W, Zhuang H, et al. Facet joint arthropathy demonstrated on FDG-PET. Clin Nucl Med. 2006;31:418–419
  111. Knockaert DC, Vanneste LJ, Vanneste SB, et al. Fever of unknown origin in the 1980s (An update of the diagnostic spectrum). Arch Intern Med. 1992;152:51–55
  112. de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO) (I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria The Netherlands FUO Study Group). Medicine (Baltimore). 1997;76:392–400
  113. Kazanjian PH. Fever of unknown origin: Review of 86 patients treated in community hospitals. Clin Infect Dis. 1992;15:968–973
  114. Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis. 1997;24:291–300quiz 301-292
  115. Cunha BA. Fever of unknown origin. Infect Dis Clin North Am. 1996;10:111–127
  116. Jones HA, Marino PS, Shakur BH, et al. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J. 2003;21:567–573
  117. Kicska G, Zhuang H, Alavi A. Acute bronchitis imaged with F-18 FDG positron emission tomography. Clin Nucl Med. 2003;28:511–512
  118. Chen DL, Schuster DP. Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L834–L840
  119. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293–321
  120. Lin EC, Quaife RA. FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med. 2001;26:241–242
  121. Raman S, Nunez R, Oliver Wong C, et al. F-18 FDG positron emission tomographic image of an aortic aneurysmal thrombus. Clin Nucl Med. 2002;27:213–214
  122. Bhargava P, Kumar R, Zhuang H, et al. Catheter-related focal FDG activity on whole body PET imaging. Clin Nucl Med. 2004;29:238–242
  123. Chang KJ, Zhuang H, Alavi A. Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med. 2000;25:838–839
  124. Mathew AS, El-Haddad G, Lilien DL, et al. Costosternal chondrodynia simulating recurrent breast cancer unveiled by FDG PET. Clin Nucl Med. 2008;33:330–332
  125. Shih WJ, Ghesani N, Hongming Z, et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: Before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med. 2002;27:142–143
  126. Belakhlef A, Jani C, Church C, et al. Fat necrosis mimicking B-cell lymphoma: A PET/CT and FDG study. Clin Nucl Med. 2008;33:271–272
  127. Yu JQ, Zhuang H, Xiu Y, et al. Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin Nucl Med. 2004;29:209–210
  128. Nakajo M, Jinnouchi S, Noguchi M, et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med. 2007;32:282–285
  129. Serizawa I, Inubushi M, Kanegae K, et al. Lymphadenopathy due to amyloidosis secondary to Sjogren syndrome and systemic lupus erythematosus detected by F-18 FDG PET. Clin Nucl Med. 2007;32:881–882
  130. Yu JQ, Milestone BN, Parsons RB, et al. Findings of intramediastinal gossypiboma with F-18 FDG PET in a melanoma patient. Clin Nucl Med. 2008;33:344–345
  131. Niederkohr RD, Hwang BJ, Quon A. FDG PET/CT detection of a gossypiboma in the neck. Clin Nucl Med. 2007;32:893–895
  132. Hayasaka K, Nihashi T, Takebayashi S, et al. FDG PET in Lhermitte-Duclos disease. Clin Nucl Med. 2008;33:52–54
  133. Repko BM, Tulchinsky M. Increased F-18 FDG uptake in resolving atraumatic bilateral adrenal hemorrhage (hematoma) on PET/CT. Clin Nucl Med. 2008;33:651–653
  134. Bagga S. Baker cyst as seen on a PET/CT scan. Clin Nucl Med. 2008;33:64–65
  135. Post MC, Grutters JC, Verzijlbergen JF, et al. PET scintigraphy of etoposide-induced pulmonary toxicity. Clin Nucl Med. 2007;32:683–684
  136. Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: Detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol. 2008;10:131–137
  137. Pellegrino D, Bonab AA, Dragotakes SC, et al. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med. 2005;46:1522–1530
  138. Radu CG, Shu CJ, Nair-Gill E, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med. 2008;14:783–788

PII: S0001-2998(08)00123-2

doi: 10.1053/j.semnuclmed.2008.10.006

Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 124-145 , March 2009

Article Tools

* Image Usage & Resolution